Last updated: June 23, 2026
Endo v. Fresenius Kabi (1:24-cv-01065) Litigation Summary and Patent-Infringement Exposure Analysis
Executive summary
Endo Operations Limited is the plaintiff in Endo Operations Limited v. FK Fresenius Kabi USA, LLC, case 1:24-cv-01065. The matter is pending in the U.S. District Court for the Southern District of Texas. The case is framed as a patent infringement dispute involving a Fresenius Kabi USA product and Endo’s asserted IP.
No further case-specific docket facts (asserted patents, claims, drug product, Orange Book listing, scheduled Markman, stay status, PTAB activity, settlement, or filings) are available in the provided input, so a complete infringement, validity, and exclusivity exposure analysis cannot be produced.
What does Endo Operations Limited v. FK Fresenius Kabi USA, LLC (1:24-cv-01065) allege?
Answer: The provided case identifier indicates a pending IP dispute, but the complaint’s substantive allegations cannot be extracted from the input.
What typically sits inside an endo v. fresenius kabi patent case filing?
- Asserted patent list (composition, method-of-use, formulation, or manufacturing)
- Alleged infringing product(s) and dosage form(s)
- Claim charts and infringement theories (literal infringement and/or equivalents)
- Induced infringement and/or contributory infringement
- Requested relief (injunction, damages, attorneys’ fees)
- Case posture items tied to Hatch-Waxman (often including a Paragraph IV or forfeiture narrative)
Which patents are asserted in 1:24-cv-01065 and how strong is the patent estate?
Answer: The asserted patent numbers and assignees are not provided in the input, so patent strength and remaining-life analysis cannot be stated.
What is needed for a strength view
- Patent numbers and prosecution history signals (claim narrowing, continuations, terminal disclaimers)
- Remaining expiration dates and PTA/PTAB events
- Claim coverage breadth (independent claim scope, dependent claim dependencies)
- Prior art landscape and enablement best-practice signals
- Known validity challenges in the same patent family
What litigation timeline does 1:24-cv-01065 follow (motions, hearings, scheduling)?
Answer: The input does not include docket events, so timeline reconstruction is not possible.
Docket events that drive outcomes in these cases
- Initial complaint and service
- Answer and defenses (invalidity, non-infringement, unenforceability)
- Rule 12 motions
- Scheduling order, discovery cutoff, expert deadlines
- Markman claim construction
- Summary judgment motions
- Pretrial and trial dates, or settlement-triggered dismissal
Is there an Orange Book / Hatch-Waxman pathway at issue in Endo v. Fresenius Kabi?
Answer: The input does not include the FDA listing or Orange Book entries, so Hatch-Waxman linkage cannot be confirmed.
How these cases usually connect to FDA regulatory filings
- Orange Book patent listing tied to a listed drug
- Alleged Paragraph IV certification (or amendments)
- FDA approval timing and launch triggers
- 30-month stay or litigation-based exclusivity mechanics
What generic entry risks exist for Fresenius Kabi if Endo’s patents are upheld?
Answer: Product and patent coverage details are not provided, so risk cannot be quantified.
What the commercial risk depends on
- Whether the product is approved for the same active ingredient and dosage form
- Claim scope alignment with the proposed generic or authorized product
- Whether a design-around is blocked by formulation or manufacturing claims
- Remedies posture (injunction scope, carve-outs, ongoing sales during litigation)
What settlement and consent-dismissal patterns are typical for this dispute type?
Answer: No settlement terms or dismissal filings are included in the input.
Common endgames that show up in similar cases
- Early settlement with license and fixed payment or running royalties
- Stipulated dismissal with a trigger date tied to launch or approval
- Consent injunction or partial resolution limited to specific patents or claims
How do courts evaluate infringement and validity in cases like 1:24-cv-01065?
Answer: The input provides no claim and product specifics, so case-specific evaluation cannot be rendered.
Typical legal and technical pivots
- Claim construction and whether the accused product meets every limitation
- Indefiniteness, written description, and enablement challenges
- Obviousness combinations in view of the prior art
- Inequitable conduct allegations (if pleaded)
- Design-around feasibility (formulation, process, or method-of-use divergence)
Which jurisdictions are covered by the court’s order in 1:24-cv-01065?
Answer: The dispute is pending in federal court; however, the input contains no information about injunction scope or regional limitation requests.
Scope considerations that matter commercially
- Whether injunctive relief is directed at distribution in the U.S.
- Whether multiple SKUs are enjoined or only specific strengths/dosage forms
- Whether the order is tied to a specific FDA label
How does Endo v. Fresenius compare with other Endo litigation against generics?
Answer: No comparative dataset is provided, and no asserted-patent or product detail is available from the input.
What comparison requires
- Same asserted patent family or overlapping claim sets
- Same active ingredient or same dosage form
- Similar procedural posture (Markman outcome often drives comparables)
Key Takeaways
- Case status: Endo Operations Limited vs. FK Fresenius Kabi USA, LLC, 1:24-cv-01065 is a pending patent dispute in U.S. federal court (forum indicated by the case identifier).
- No asserted-patent detail available: The input does not provide patent numbers, claims, product identity, or docket milestones, so no expiration, validity, infringement strength, or launch-risk analysis can be stated.
- Actionability depends on filings: A litigation and exposure view requires complaint and schedule specifics, including asserted patents, the accused product description, and procedural milestones.
FAQs
- What does a Paragraph IV certification change in a case like Endo v. Fresenius Kabi?
- How does Markman claim construction typically shift outcomes in pharmaceutical patent litigation?
- What remedies do plaintiffs pursue in generic-competition patent suits (injunction vs. damages)?
- How do formulation or manufacturing method patents affect generic design-around strategies?
- What procedural steps most often resolve Hatch-Waxman-related patent cases before trial?
References
- Endo Operations Limited v. FK Fresenius Kabi USA, LLC, No. 1:24-cv-01065 (S.D. Tex.).
